Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.

Cancer science - 1 Jul 2014

Kaneto Naoki, Yokoyama Satoru, Hayakawa Yoshihiro, Kato Shinichiro, Sakurai Hiroaki, Saiki Ikuo

Abstract excerpt

Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (EGFR-TKI), including gefitinib, provide a significant clinical benefit in non-small-cell lung cancer (NSCLC) patients, the acquisition of drug resistance has been known to limit the efficacy of EGFR-TKI therapy. In this study, we demonstrated the involvement of EGF-EGFR signaling in NSCLC cell migration and the requirement of RAC1 in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Movement
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to EGF gene

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 24750242
DOI: 10.1111/cas.12425
PMCID: PMC4317907

Genes

EGFR
RAC1
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.PMID 24750242Read ↗

Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLCSemantic proximity Read ↗

Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLCSemantic proximity Read ↗

Rational design and applications of a Rac GTPase-specific small molecule inhibitor.Semantic proximity Read ↗

A PI3K- and GTPase-independent Rac1-mTOR mechanism mediates MET-driven anchorage-independent cell growth but not migrationSemantic proximity Read ↗

Knockdown of TRAF1 in NSCIC Contributes Gefitinib Sensitivity by Promoting G2/M Cell Cycle ArrestSemantic proximity Read ↗

RacGAP1-driven focal adhesion formation promotes melanoma transendothelial migration through mediating adherens junction disassembly.Semantic proximity Read ↗

MEK inhibitors and DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, prevent the migration and invasion of KRAS-mutant cancer cells.Semantic proximity Read ↗

Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor.Semantic proximity Read ↗

PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.Semantic proximity Read ↗

Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells.Semantic proximity Read ↗

Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.Semantic proximity Read ↗

Extracellular signal-regulated kinase regulates RhoA activation and tumor cell plasticity by inhibiting guanine exchange factor H1 activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.